This review provides an overview of atrial fibrillation management, emphasizing the growing interest in non-pharmacological electrophysiological therapies to overcome the limitations of traditional pharmacological options.
Answers are grounded in this paper and cite their sources.
May support interest in non-pharmacological AF therapies; leaves open comparative efficacy versus pharmacotherapy.
Atrial fibrillation (AF) is the most common sustained arrhythmia. Its prevalence is increasing and accordingly, so is its burden on healthcare systems throughout the world. The pathophysiology of AF is complex and poorly understood, which of itself presents a major challenge to the management of this important condition. AF is associated with increased morbidity and mortality, particularly in patients with underlying left ventricular dysfunction. Once AF occurs, it is often difficult to 'cure' and as such, the major focus of therapy is currently divided essentially between a rate control strategy and a need to revert to and maintain sinus rhythm. Both approaches seek to minimise the associated symptoms and complications. Over the past two decades, numerous pharmacological approaches to the management of AF have been employed, many of which have been shown to be relatively ineffective or confounded by major complications. Accordingly, recent research and interest has focused on non-pharmacological electrophysiological therapies to either cure AF or improve symptoms. This review summarises the current approaches to the management AF and provides some new insights into emerging therapies for this common clinical problem.
No takes yet. Share an insight, caveat, or question.
Gould et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: